BioXcel Therapeutics
BTAI
93 hedge funds and large institutions have $283M invested in BioXcel Therapeutics in 2021 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 36 increasing their positions, 23 reducing their positions, and 24 closing their positions.
67% more call options, than puts
Call options by funds: $4.8M | Put options by funds: $2.88M
57% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 23
0.25% more ownership
Funds ownership: 2.86% → 3.11% (+0.25%)
10% less funds holding
Funds holding: 103 → 93 (-10)
27% less capital invested
Capital invested by funds: $388M → $283M (-$105M)
38% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$13.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$11M |
| 3 |
Morgan Stanley
New York
|
+$3.06M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$2.07M |
| 5 |
BlackRock
New York
|
+$1.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$1.8M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.65M |
| 3 |
B
Bailard
Foster City,
California
|
-$1.4M |
| 4 |
ACM
ACT Capital Management
Wayne,
Pennsylvania
|
-$805K |
| 5 |
AS
Altshuler Shaham
Tel Aviv,
Israel
|
-$744K |
BTAI Hedge Fund Activity: Q4 2021 in Review
93 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q4 2021, worth a combined $283M — down 27% from $388M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of BTAI and 15 opened new positions — a net loss of 9 holders — while 23 trimmed existing stakes and 36 added.
The largest buyer was AllianceBernstein, adding an estimated $13.1M. The largest seller was GSA Capital Partners, exiting entirely with an estimated $1.8M sold.
- 93 institutional investors held BioXcel Therapeutics (BTAI) as of Q4 2021, down from 103 in Q3 2021.
- Funds reported $283M of BioXcel Therapeutics stock for Q4 2021, down 27% quarter-over-quarter.
- 15 funds opened new BioXcel Therapeutics positions in Q4 2021 and 24 closed out, a net change of -9 holders.
- The largest BioXcel Therapeutics buyer in Q4 2021 was AllianceBernstein, an estimated $13.1M added.
- The largest BioXcel Therapeutics seller in Q4 2021 was GSA Capital Partners, an estimated $1.8M sold.
Based on aggregated 13F filings for Q4 2021.